Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

Innate proposes U.S. listing
Innate Pharma S.A. (Euronext:IPH) filed to raise up to $100 million total across a NASDAQ listing and a European private placement. The antibody company markets CD22-targeted

Read the full 291 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE